The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice
Open accessAbstract
Excessive production of triglyceride-rich VLDL is attributable to hypertriglyceridemia. VLDL production is facilitated by microsomal triglyceride transfer protein (MTP) in a rate-limiting step that is regulated by insulin. To characterize the underlying mechanism, we studied hepatic MTP regulation by forkhead box O1 (FoxO1), a transcription factor that plays a key role in hepatic insulin signaling. In HepG2 cells, MTP expression was induced by FoxO1 and inhibited by exposure to insulin. This effect correlated with the ability of FoxO1 to bind and stimulate MTP promoter activity. Deletion or mutation of the FoxO1 target site within the MTP promoter disabled FoxO1 binding and resulted in abolition of insulin-dependent regulation of MTP expression. We generated mice that expressed a constitutively active FoxO1 transgene and found that increased FoxO1 activity was associated with enhanced MTP expression, augmented VLDL production, and elevated plasma triglyceride levels. In contrast, RNAi-mediated silencing of hepatic FoxO1 was associated with reduced MTP and VLDL production in adult mice. Furthermore, we found that hepatic FoxO1 abundance and MTP production were increased in mice with abnormal triglyceride metabolism. These data suggest that FoxO1 mediates insulin regulation of MTP production and that augmented MTP levels may be a causative factor for VLDL overproduction and hypertriglyceridemia in diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420513 · Cited by 698
Metabolic Syndrome: A Clinical and Molecular Perspective
Moller, D. E., & Kaufman, K. D. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104751 · Cited by 631
Hyperlipidemic Effects of Dietary Saturated Fats Mediated through PGC-1β Coactivation of SREBP
Lin, J., Yang, R., Tarr, P. T., Wu, P.-H., Handschin, C., Li, S., Yang, W., Pei, L., Uldry, M., Tontonoz, P., et al. (2005) · Cell · doi:10.1016/j.cell.2004.11.043 · Cited by 625
Nakae, J., Biggs, W. H., Kitamura, T., Cavenee, W. K., Wright, C. V. E., Arden, K. C., & Accili, D. (2002) · Nature Genetics · doi:10.1038/ng890 · Cited by 616
Matsumoto, M., Pocai, A., Rossetti, L., DePinho, R. A., & Accili, D. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.08.006 · Cited by 615
FoxO proteins in insulin action and metabolism
Barthel, A., Schmoll, D., & Unterman, T. G. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.03.010 · Cited by 604
Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
Hussain, M. M., Shi, J., & Dreizen, P. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r200014-jlr200 · Cited by 591
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580
Molecular Mechanisms Regulating Hormone-Sensitive Lipase and Lipolysis
Holm, C., Østerlund, T., Laurell, H., & Contreras, J. A. (2000) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.20.1.365 · Cited by 564
Cited by
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Begriche, K., Massart, J., Robin, M.-A., Borgne-Sanchez, A., & Fromenty, B. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.006 · Cited by 555
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
“Acute inhibitory effects of insulin on lipid production are essential for rapid hepatic adaptation to metabolic shifts between fasting and refeeding to maintain plasma lipids within an optimal physiologic range.(29) Thus, insulin resistant adults have higher and more prolonged postprandial excursions of very–lowdensit…”
BackgroundThe role of FoxO in the regulation of metabolism
Gross, D. N., van den Heuvel, A. P. J., & Birnbaum, M. J. (2008) · Oncogene · doi:10.1038/onc.2008.25 · Cited by 540
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Choi, S. H., & Ginsberg, H. N. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.007 · Cited by 418
Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, et al. (2015) · Nature Communications · doi:10.1038/ncomms7498 · Cited by 368
FoxO integration of insulin signaling with glucose and lipid metabolism
Lee, S., & Dong, H. H. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0002 · Cited by 360
Self-citationFoxo1 integrates insulin signaling with mitochondrial function in the liver
Cheng, Z., Guo, S., Copps, K., Dong, X., Kollipara, R., Rodgers, J. T., Depinho, R. A., Puigserver, P., & White, M. F. (2009) · Nature Medicine · doi:10.1038/nm.2049 · Cited by 321
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272
Hypolipidemic effects of proanthocyanidins and their underlying biochemical and molecular mechanisms
Bladé, C., Arola, L., & Salvadó, M. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900476 · Cited by 253
New insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194
Postprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling
Matveyenko, A. V., Liuwantara, D., Gurlo, T., Kirakossian, D., Dalla Man, C., Cobelli, C., White, M. F., Copps, K. D., Volpi, E., Fujita, S., et al. (2012) · Diabetes · doi:10.2337/db11-1462 · Cited by 163
Sundaram, M., & Yao, Z. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-35 · Cited by 154
FoxO1 integrates insulin signaling to VLDL production.
Kamagate, A., & Dong, H. H. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6882 · Cited by 127
Self-citationApolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100
“Fourth, the dysregulated FoxO1 signalling is unable to attenuate MTP and apo C-III expression [41,47].”
BackgroundMyeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis
Lee, S., Usman, T. O., Yamauchi, J., Chhetri, G., Wang, X., Coudriet, G. M., Zhu, C., Gao, J., McConnell, R., Krantz, K., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154333 · Cited by 64
“Likewise, FoxO1 upregulation is detectable in the liver, correlating with the pathogenesis of NAFL, in a number of models including dietary obese mice, diabetic db/db mice, and high fructose–fed hamsters (33, 36, 52).”
BackgroundSelf-citationChung, S., Timmins, J. M., Duong, M., Degirolamo, C., Rong, S., Sawyer, J. K., Singaraja, R. R., Hayden, M. R., Maeda, N., Rudel, L. L., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.096933 · Cited by 60
Charidemou, E., Ashmore, T., Li, X., McNally, B. D., West, J. A., Liggi, S., Harvey, M., Orford, E., & Griffin, J. L. (2019) · JCI Insight · doi:10.1172/jci.insight.124819 · Cited by 52
“The production of hepatic, but not intestinal, apolipoprotein CIII is also controlled by FoxO1 via the –498/–403 element in the apoC3 promoter (41, 43).”
BackgroundInsulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
“In mice that express a constitutively active form of FOXO1, MTTP expression is induced, and VLDL production and its subsequent secretion are enhanced (148).”
Hepatic ABCA1 and VLDL triglyceride production
Liu, M., Chung, S., Shelness, G. S., & Parks, J. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.020 · Cited by 43
“Forkhead box 01 (Fox01) is a transcription factor that stimulates hepatic MTP expression, increasing VLDL production by the liver [85].”
Feng, B., He, Q., & Xu, H. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.06.001 · Cited by 37
Metadata
- Authors
- Kamagate, A., Qu, S., Perdomo, G., Su, D., Kim, D. H., Slusher, S., Meseck, M., & Dong, H. H.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-05-01
- Volume
- 118
- Issue
- 6
- Pages
- 2347-64
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2132961868
- Cited by
- 282
- References
- 80
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.